Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 18/20 | 0.80 |
| ▸ | ABL1 | P00519 | 6/20 | 0.61 |
| ▸ | EGFR | P00533 | 6/20 | 0.61 |
| ▸ | ABL2 | P42684 | 6/20 | 0.61 |
| ▸ | KDR | P35968 | 1/20 | 0.61 |
| ▸ | CDK1 | P06493 | 3/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7836043 | 0.93 | SRC (0.89) | SRCABL1EGFRABL2CDK1 | |
| SCHEMBL7846964 | 0.91 | SRC (0.70) | SRCABL1EGFRABL2KDR | |
| SCHEMBL7846544 | 0.91 | SRC (0.74) | SRCABL1EGFRABL2KDR | |
| SCHEMBL7842886 | 0.89 | SRC (0.69) | SRCABL1EGFRABL2KDR | |
| SCHEMBL7833796 | 0.89 | SRC (0.71) | SRCABL1EGFRABL2KDR | |
| SCHEMBL7844214 | 0.89 | SRC (0.71) | SRCABL1EGFRABL2KDR | |
| SCHEMBL7835012 | 0.87 | SRC (0.64) | SRCABL1EGFRABL2KDR | |
| SCHEMBL7842432 | 0.87 | SRC (0.73) | SRCABL1EGFRABL2KDR | |
| SCHEMBL7845253 | 0.87 | SRC (0.69) | SRCABL1EGFRABL2KDR | |
| SCHEMBL7844695 | 0.87 | SRC (0.68) | SRCABL1EGFRABL2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0783505-B1 | PYRROLO[2,3-d]PYRIMIDINES AND THEIR USE | NOVARTIS AG (CH) | 2001-03-07 | — | — | EP | disclosed |
| EP-0783505-A1 | PYRROLO[2,3-d]PYRIMIDINES AND THEIR USE | Novartis AG (CH) | 1997-07-16 | — | — | EP | disclosed |
| WO-1996010028-A1 | PYRROLO[2,3-d]PYRIMIDINES AND THEIR USE | NOVARTIS AG (CH) | 1996-04-04 | — | — | WO | disclosed |